Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
1.870
-0.120 (-6.03%)
At close: Sep 12, 2025, 4:00 PM EDT
1.898
+0.028 (1.51%)
After-hours: Sep 12, 2025, 7:37 PM EDT
Equillium Revenue
Equillium had revenue of $16.55M in the twelve months ending June 30, 2025, down -61.16% year-over-year. In the year 2024, Equillium had annual revenue of $41.10M with 13.89% growth.
Revenue (ttm)
$16.55M
Revenue Growth
-61.16%
P/S Ratio
4.02
Revenue / Employee
$472,943
Employees
35
Market Cap
111.27M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 41.10M | 5.01M | 13.89% |
Dec 31, 2023 | 36.08M | 20.33M | 128.97% |
Dec 31, 2022 | 15.76M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
EQ News
- 11 days ago - Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 16 days ago - Equillium to Participate in the Cantor Global Healthcare Conference 2025 - Business Wire
- 17 days ago - Equillium: Pushing Forward With AhR Activation Drug Candidate EQ504 For UC - Seeking Alpha
- 4 weeks ago - Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic - Business Wire
- 5 weeks ago - Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy - Business Wire
- 4 months ago - Equillium Announces Multiple Poster Presentations Highlighting EQ504 at the Annual Meeting of The American Association of Immunologists - Business Wire
- 4 months ago - Equillium Announces New Aryl Hydrocarbon Receptor Modulator Program EQ504 - Business Wire
- 5 months ago - Equillium Announces Feedback from the U.S. Food and Drug Administration - Business Wire